Endogenex, Inc. — SEC Form D Filing

Endogenex, Inc. filed an SEC Form D on November 5, 2026, reporting $132.35M raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
November 5, 2026
Amount reported
$132.35M
Round stage
Series B+
Industry
Medical Devices
Website
https://www.endogenex.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Over 400 million people live with type 2 diabetes worldwide, and approximately half suffer from poorly controlled blood glucose levels due to a lack of sustainable treatment options that address underlying metabolic signaling.

Solution

Endogenex is developing an endoscopic system that delivers precise, non-thermal pulsed electric fields (PEF) to the duodenum. This therapy is designed to eliminate poorly functioning signaling cells and harness the body's natural regenerative abilities to restore metabolic function and blood glucose control.

Why now

Rising global rates of type 2 diabetes and the high economic and health burden of long-term medication dependence are driving demand for minimally invasive procedural interventions that target the root causes of metabolic disease.

Verdict

Investors funded this round on the premise that pulsed electric field ablation eliminates the safety hazards of thermal mucosal resurfacing while capturing a durable, drug-free metabolic reset. The syndicate placed a massive clinical bet that non-thermal cellular regeneration in the duodenum could deliver pharmaceutical-grade glycemic reductions without chronic compliance overhead. This cleared because PEF offered a cleaner procedural safety profile than legacy thermal ablation devices, not because health systems were clamoring to route diabetic patients into outpatient endoscopy suites over pharmacotherapy. Commercial upside remains capped by stubborn referral friction between endocrinologists and gastroenterologists.

Source: SEC EDGAR Form D filing